A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
NCT ID: NCT07040059
Last Updated: 2025-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
18 participants
INTERVENTIONAL
2025-03-22
2028-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction
NCT04661150
A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer
NCT01748773
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
NCT01351038
A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer
NCT01710592
Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC): Her+XELOX
NCT01396707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In the study Part 2 (Phase 2), the efficacy of AUR103 calcium in combination with Trastuzumab and CAPOX will be evaluated in HER2-positive gastric or gastroesophageal junction adenocarcinoma patients. The part 2 (Phase 2) of the study will be a randomized study which will start after part 1 (Phase 1b). In the study part 2 (Phase 2), there will either 1 or 2 treatment arm(s) and one control arm (Trastuzumab + CAPOX). The number treatment arms will be based on the phase 1b data. However, the treatment patients in the Phase 2 will receive the study drug along with Trastuzumab and CAPOX.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1b (Cohort 1: AUR103 Calcium 200 mg BID with standard dose of Trastuzumab and CAPOX.
Phase 1b: Cohort 2 (AUR103 Calcium 300 mg BID with standard dose of Trastuzumab and CAPOX). Cohort 2 of Phase 1b will start after completion of dose-limiting toxicity (DLT) period of Cohort 1.
AUR103 Calcium
AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
Phase 2 Treatment Arm
Phase 2 (Experimental Arm) - Either one or two treatment arm(s) selected from the Phase 1b part.
AUR103 Calcium
AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
Phase 2 Control Arm
Phase 2 will have control arm (with standard dose of Trastuzumab and CAPOX).
Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)
Standard dose of Trastuzumab and CAPOX (Capecitabine + Oxaliplatin) will be administered in the Control Arm of Phase 2.
Phase 1b (Cohort 2: AUR103 Calcium 300 mg BID with standard dose of Trastuzumab and CAPOX.
AUR103 Calcium
AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
Phase 1b: Cohort 3 (AUR103 Calcium 400 mg BID with standard dose of Trastuzumab and CAPOX).
Phase 1b: Cohort 3 (AUR103 Calcium 400 mg BID with standard dose of Trastuzumab and CAPOX). Cohort 3 of Phase 1b will start after completion of dose-limiting toxicity (DLT) period of Cohort 2.
AUR103 Calcium
AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AUR103 Calcium
AUR103 Calcium will be administered with standard dose of Trastuzumab and CAPOX (Capecitabine and oxaliplatin).
Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)
Standard dose of Trastuzumab and CAPOX (Capecitabine + Oxaliplatin) will be administered in the Control Arm of Phase 2.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female patients aged greater than or equal to 18 years.
3. Patients must meet the following criteria for each of the respective parts of the study:
a) Pathological diagnosis of a HER2-positive, unresectable locally advanced or metastatic, gastric / gastroesophageal (GE) junction adenocarcinoma.
\[Note: For patients who have already undergone HER2 testing, it does not need to be repeated. For patients who have not undergone HER2 testing, the same can be done as part of pre-screening, after taking informed consent\].
B) Patients must NOT have received any systemic anti-cancer therapy for the treatment of gastric or gastroesophageal (GE) junction adenocarcinoma.
\[Note: The partial resection of tumor or debulking surgery is allowed but any therapeutic chemotherapy or systemic anti-cancer therapy is not allowed\].
4. Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1.
5. Acceptable bone marrow as described below:
1. ANC greater than or equal to 1500/μL (without WBC growth factor support).
2. Platelet count greater than or equal to 100,000/μL (without transfusion support).
3. Hemoglobin greater than or equal to 9 g/dL (Transfusion is allowed to achieve this Hb).
6. Acceptable organ function as described below:
1. Total Bilirubin less than or equal to 1.5 x ULN (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin less than or equal to 2.5 x ULN).
2. AST (SGOT) less than or equal to 3 x ULN (less than or equal to 5 × ULN if known liver metastases).
3. ALT (SGPT) less than or equal to 3 x ULN (less than or equal to 5 × ULN if known liver metastases).
4. Creatinine clearance (CrCl) greater than or equal to 60 mL/min (either measured or estimated by the Cockcroft-Gault formula). (Cockcroft-Gault formula for estimated creatinine clearance \[eCrCl\]: eCrCl = \[140 - Age\] × Weight \[kg\] × \[0.85 if Female\] / \[72 × serum creatinine (mg/dL)\]).
5. Albumin greater than or equal to 3.0 g/dL.
7. Evidence of measurable disease as per Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 \[Note: Measurable disease for solid tumors is defined as at least one lesion that can be accurately measured in at least 1 dimension with a minimum size of 10 mm for non-nodal lesions or 15 mm in short axis for nodal lesions\].
8. Patients who have not undergone HER2 testing must be willing and able to provide an adequate archived tumor tissue sample or a fresh tumor tissue sample to confirm HER2 status.
\[Note: If archived sample is not available, and HER2 testing has not been done, then patient must agree to submit fresh tumor sample for an assessment of HER2 status\].
9. Left ventricular ejection fraction (LVEF) greater than or equal to 50% by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan at Screening.
10. Ability to swallow and retain oral medications.
11. Negative serum pregnancy test in women of childbearing potential (WOCBP).
12. Women of childbearing potential and men who partner with such a woman of childbearing potential must agree to use one or more of highly effective method(s) for contraception for the duration of the study, i.e., through 28-day follow up visit, after discontinuation of study drug(s).
Exclusion Criteria
2. Exposed to definitive radiotherapy \[Note: Palliative radiotherapy is allowed\].
3. Use of any investigational agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
4. Known central nervous system (CNS) metastases.
5. Major surgery less than or equal to 28 days from Cycle 1 Day 1 (Major surgery is defined as a procedure requiring general anaesthesia).
6. Known to be human immunodeficiency virus (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
7. Known active or chronic hepatitis B or hepatitis C infection.
8. Uncontrolled congestive heart failure (New York Heart Association \[NYHA\] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or transient ischemic attack, or pulmonary embolism within 3 months prior to Cycle 1 Day 1.
9. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in past 3 months, before Cycle 1 Day 1.
10. The QTcF (corrected QT interval Fridericia method) value in the screening ECG more than 460 ms in males and females.
11. Currently taking warfarin or other oral coumarin-derivative anticoagulant therapy.
12. Patients with peripheral neuropathy of Grade greater than or equal to 2.
13. Patients with severe obstructive pulmonary disease, pulmonary fibrosis, or interstitial lung disease.
14. Patients with poorly controlled hypertension, defined as systolic blood pressure more than or equal to 160 mmHg or diastolic blood pressure more than 100 mmHg.
15. Previous or concomitant additional malignancy, except for basal cell or squamous cell carcinoma of the skin or carcinoma-in-situ of the uterine cervix; patients with other malignancies are eligible if they have remained disease free for at least 2 years prior to trial entry and in the opinion of the investigator deemed to have a low likelihood of recurrence.
16. Any clinically significant medical, psychiatric, or social condition; or laboratory abnormality that may increase the risk of trial participation or may interfere with the informed consent process and/or with compliance with the requirements of the trial or may interfere with the interpretation of the trial results and, in the Investigator's opinion, would make the patient inappropriate for entry into this trial.
17. Pregnant or lactating women.
18. Current swab-positive or suspected (under investigation) COVID19 infection or fever and other signs or symptoms suggestive of COVID-19 infection with recent contact of person(s) with confirmed COVID-19 infection, at screening or Cycle 1 Day 1.
19. Patients with any known contraindication to receive trastuzumab, or capecitabine, or oxaliplatin.
20. Known hypersensitivity to trastuzumab, capecitabine, oxaliplatin, or to any of its components.
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aurigene Discovery Technologies Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Akhil Kumar
Role: PRINCIPAL_INVESTIGATOR
Aurigene Oncology Limited
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
HCG Cancer Center
Vizag, Andhra Pradesh, India
Shalby Hospital
Ahmedabad, Gujarat, India
The Gujarat Cancer & Research Insititute
Ahmedabad, Gujarat, India
Kiran Hospital Multi Super Speciality Hospital & Reseach Center
Surat, Gujarat, India
Asha Hospital and Research Centre
Bangalore, Karnataka, India
Karnataka Cancer Hospital and Radiation Theraphy Center
Bangalore, Karnataka, India
Netaji Subhas Chandra Bose Cancer Hospital
Kolkata, West Bengal, India
Hope & Heal Cancer Hospital and Research Center
Siliguri, West Bengal, India
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AUR103-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.